FDA有关骨质疏松药物二磷酸盐的使用期及相关保健知识

FDA呼吁进一步研究骨质疏松药物二磷酸盐的使用期。一项回顾认为相对年轻的骨质疏松患者如没有骨折病史，骨密度接近正常的，服药3-5年后可以停药。相反，年老的、有骨折病史的骨质疏松患者，服用时间长些可能更有益处。但到底什么时候停药最合理没有定论。

来源: http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm309688.htm

An FDA review of clinical studies measuring the effectiveness of long-term bisphosphonates use shows that some patients may be able to stop using bisphosphonates after three to five years and still continue to benefit from their use, says Marcea Whitaker, M.D., a medical officer at FDA’s Center for Drug Evaluation and Research. Whitaker is one of the co-authors of the FDA review, which was published in the May 31, 2012 issue of The New England Journal of Medicine.
......

The studies suggest that patients at low risk of fracture (for example, younger patients without a fracture history and with a bone mineral density approaching normal) may be good candidates for discontinuation of bisphosphonate therapy after three to five years.

In contrast, patients at increased risk for fractures (for example, older patients with a history of fracture and a bone mineral density remaining in the osteoporotic range) may benefit further from continued bisphosphonate therapy.

FDA 也顺便科普了减少骨质疏松风险的做法 (这是中国FDA(CFDA)所缺乏的，不向大众正面传播药物和健康保健科普知识。所以网上的垃圾帖通过媒体/网络/微信横行神州大地，醉着晕着我中华子民。):

相关信息:

• Bisphosphonates Information
• Safety update: osteoporosis drugs, bisphosphonates, and atypical fractures
• possible Fracture Risk With Osteoporosis Drugs

 

所有跟帖： 

• 是病从口入, 不是缺医少药! -probiotic- ♂ (0 bytes) () 05/14/2014 postreply 17:01:49